Four things to know:
1. MagnetOs is an implantable bone graft with submicron surface topography that supports the formation of bone, rather than scar tissue.
2. Preclinical models demonstrated MagnetOs’ ability to form bone in soft tissues without the need for added cells or growth factors.
3. Kuros Biosciences will also feature Fibrin-PTH, which was approved by the FDA for a Phase 2a clinical trial in September.
4. Fibrin-PTH consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor, designed to apply onto and around an intervertebral body fusion device as a gel.
More articles on devices:
Dr. Isaac Karikari: Changing attitudes toward opioids and how physicians can drive change
Dr. Timothy Kremchek to operate on Reds rookie Nick Senzel — 4 insights
Icotec to introduce new pedicle screw system — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.